PreludeDx Announces Publication in Breast Cancer Research Validating AidaBreast™, the Only Multi-Omic Test to Predict Locoregional Recurrence Risk and Radiation Therapy Benefit in Early-Stage Invasive Breast Cancer Hand-out Mar 12, 2026 Mar 12, 2026 Updated Mar 12, 2026 Facebook Twitter WhatsApp SMS Email Print Copy article link Save PreludeDx Hand-out Tags Logo As featured on PreludeDx Announces Publication in Breast Cancer Research Validating AidaBreast™, the Only Multi-Omic Test to Predict Locoregional Recurrence Risk and Radiation Therapy Benefit in Early-Stage Invasive Breast Cancer LAGUNA HILLS, Calif., March 12, 2026 Facebook Twitter WhatsApp SMS Email Print Copy article link Save Sections AutomotiveBridalBusiness And CareersCommunity CaresEducationEspanolFamily LivingFashion, Beauty & FitnessFood, Recipes & EntertainingGift IdeasGreen LivingHealth & WellnessHome DecoratingHome ImprovementHot TopicsHow ToKitchen, Bed & BathLawn & GardenMoney & FinancePetsPress ReleasesReal EstateSeasonalSenior LivingSportsTech Talk & InnovationTravel
PreludeDx Announces Publication in Breast Cancer Research Validating AidaBreast™, the Only Multi-Omic Test to Predict Locoregional Recurrence Risk and Radiation Therapy Benefit in Early-Stage Invasive Breast Cancer LAGUNA HILLS, Calif., March 12, 2026
